Effects of renal replacement therapy on antimicrobial therapy

Current Clinical Pharmacology

Volumn 8, Issue 1, 2013, Pages 39-45

  Vossen, Matthias G ^a   Thalhammer, Florian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antimicrobial therapy; Hemodiafiltration; Hemodialysis; Pharmacokinetics; Renal replacement therapy

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; FLUCLOXACILLIN; FOSFOMYCIN; FUSIDIC ACID; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL KIDNEY; BODY WEIGHT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; GLOMERULUS FILTRATION RATE; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FUNCTION; LIVER METABOLISM; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; URINARY EXCRETION;

EID: 84873105491     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488413804810558     Document Type: Article

References (70)

1. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41(14): 1135-51.
2. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44(10): 1009-34.
3. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34(1): 25-56.
4. Kielstein JT, Czock D, Schöpke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med 2006; 34(1): 51-6.
5. Thalhammer F, Hörl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet 2000; 39(4): 271-9.
6. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007; 46(12): 997-1038.
7. Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 2009; 66(12 Suppl 4): S23-30.
8. Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob. Agents Chemother 1984; 25(4): 438-42.
9. Gabutti L, Taminelli-Beltraminelli L, Marone C. Clearance of ceftriaxone during hemodialysis using cuprophane, haemophane and polysulfone dialysers. Eur J Clin Pharmacol 1997; 53(2): 123-6.
10. Huang Z, Gao D, Letteri JJ, Clark WR. Blood-membrane interactions during dialysis. Semin Dial 2009 Dec; 22(6): 623-8.
11. Klinke B, Röckel A, Perschel W, et al. Beta-2-microglobulin adsorption and release in-vitro: influence of membrane material, osmolality and heparin. Int J Artif Organs 1988; 11(5): 355-60.
12. Klinke B, Röckel A, Abdelhamid S, Fiegel P, Walb D. Transmembranous transport and adsorption of beta-2-microglobulin during hemodialysis using polysulfone, polyacrylonitrile, polymethylmethacrylate and cuprammonium rayon membranes. Int J Artif Organs 1989; 12(11): 697-702.
13. Meyer B, Traunmüller F, Hamwi A, et al. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. Int J Clin Pharmacol Ther 2004; 42(10): 556-60.
14. Menth M, Röckel A, Abdelhamid S, Fiegel P, Walb D. Lowmolecular-weight protein-permeable cuprammonium rayon haemofilter. Nephrol Dial Transplant 1992; 7(8): 844-7.
15. Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989; 35(6): 1409-12.
16. Pea F, Brollo L, Lugano M, Dal Pos L, Furlanut M. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit 2001; 23(5): 587-8.
17. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol [Internet] 2011. [cited 2011 Aug 30]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21831196
18. Schmaldienst S, Traunmüller F, Burgmann H, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 2000; 56(1): 61-4.
19. Meyer B, Guttmann C, Dittrich E, Schmaldienst S, Thalhammer F. Intermittent administration of betalactam-antibiotics for treatment of severe infection in hemodialysis patients. Eur J Med Res 2005; 10(4): 140-4.
20. Soriano F. Optimal dosage of beta-lactam antibiotics: time above the MIC and inoculum effect. J. Antimicrob. Chemother 1992; 30(5): 566-9.
21. Keller F, Borner K, Schwarz A, Offermann G, Lode H. Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit 1987; 9(2): 148-53.
22. Meyer B, Ahmed el Gendy S, Delle, et al. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res 2003; 26(2): 135-40.
23. Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE. Pharmacokinetics of amoxycillin and clavulanic acid in hemodialysis patients following intravenous administration of Augmentin. Br J Clin Pharmacol 1988; 26(4): 385-90.
24. Bouman CSC, van Kan HJM, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006; 32(12): 2013-9.
25. Francke EL, Appel GB, Neu HC. Kinetics of intravenous amoxicillin in patients on long-term dialysis. Clin Pharmacol Ther 1979; 26(1): 31-5.
26. Traunmüller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J. Antimicrob. Chemother 2002; 49(1): 129-34.
27. Nikolaidis P, Tourkantonis A. Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol 1985; 24(3): 142-6.
28. Banyai M, Thalhammer F, El-Menyawi I, Heinz G, Traunmüller F, Siostrzonek P. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. Clin Pharmacol Ther 2000; 67(4): 368-72.
29. Sowinski KM, Mueller BA, Grabe DW, et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 2001; 37(4): 766-76.
30. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol 1996; 36(12): 1114-9.
31. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5): 562-77.
32. van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997; 23(8): 873-7.
33. Keller E, Fecht H, Böhler J, Schollmeyer P. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol Dial Transplant 1989; 4(7): 640-5.
34. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42(9): 2417-20.
35. Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24(1): 267-71.
36. O'Shea S, Duffull S, Johnson DW. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? Semin Dial 2009; 22(3): 225-30.
37. Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med 1990; 18(6): 675-6.
38. Robert R, Rochard E, Malin F, Bouquet S. Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med 1991; 19(4): 588-9.
39. Thalhammer F, Rosenkranz AR, Burgmann H, et al. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes. Wien Klin Wochenschr 1997; 109(10): 362-5.
40. Bellmann R, Falkensammer G, Seger C, Weiler S, Kountchev J, Joannidis M. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther 2010; 48(4): 243-9.
41. Bochud-Gabellon I, Regamey C. Teicoplanin, a new antibiotic effective against gram-positive bacterial infections of the skin and soft tissues. Dermatologica 1988; 176(1): 29-38.
42. Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 1998; 31(6): 1019-27.
43. Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989; 35(6): 1409-12.
44. Hudson JQ, Comstock TJ, Feldman GM. Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant 2004; 19(2): 400-5.
45. Alwakeel J, Najjar TA, al-Yamani MJ, Huraib S, al-Haider A, Abu-aisha H. Comparison of the effects of three hemodialysis membranes on vancomycin disposition. Int Urol Nephrol 1994; 26(2): 223-8.
46. Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA. Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997; 17(2): 256-62.
47. Meyer B, Kornek GV, Nikfardjam M, et al. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 2005; 56(1): 172-9.
48. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47(9): 2775-80.
49. Tsuji Y, Hiraki Y, Mizoguchi A, et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008; 14(2): 156-60.
50. Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66(3): 291-8.
51. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42(15): 1411-23.
52. Tsaganos T, Kouki P, Digenis P, Giamarellou H, Giamarellos-Bourboulis EJ, Kanellakopoulou K. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent hemodialysis. Int J Antimicrob Agents 2008; 32(1): 46-9.
53. Czock D, Hüsig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1(6): 1263-8.
54. Fuhrmann V, Schenk P, Mittermayer C, El Menyawi I, Ratheiser K, Thalhammer F. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients. Am J Kidney Dis 2003; 42(2): 310-4.
55. Traunmüller F, Thalhammer-Scherrer R, Locker GJ, et al. Singledose pharmacokinetics of levofloxacin during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2001; 47(2): 229-31.
56. Davies SP, Azadian BS, Kox WJ, Brown EA. Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous hemodialysis. Nephrol Dial Transplant 1992; 7(8): 848-54.
57. Ittner KP, Roth G, Gruber M, Pawlik M, Taeger K. Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro. J Antimicrob Chemother 2005; 56(2): 360-4.
58. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36(5): 353-73.
59. Brown NM, Reeves DS, McMullin CM. The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either hemodialysis or continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1997; 39(6): 803-9.
60. Gattringer R, Meyer B, Heinz G, et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother 2006; 58(2): 367-71.
61. Vilay AM, Grio M, Depestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011; 39(1): 19-25.
62. Salama NN, Segal JH, Churchwell MD, et al. Single-dose daptomycin pharmacokinetics in chronic hemodialysis patients. Nephrol Dial Transplant 2010; 25(4): 1279-84.
63. Florian Thalhammer. Antibiotika & Antiinfektiva. 5th ed. Vienna: 2009.
64. Höffler D, Koeppe P, Paeske B. Pharmacokinetics of azithromycin in normal and impaired renal function. Infection 1995; 23(6): 356-61.
65. Roberts AP, Eastwood JB, Gower PE, Fenton CM, Curtis JR. Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance hemodialysis patients and normal subjects. Eur J Clin Pharmacol 1978; 14(6): 435-9.
66. Peddie BA, Dann E, Bailey RR. The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin. Aust N Z J Med 1975; 5(3): 198-202.
67. Cimino JE, Tierno PM Jr. Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin). Appl Microbiol 1969 Mr; 17(3): 446-8.
68. Bennett WM, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DC. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, Third Edition. 3rd ed. American College of Physicians; 1992.
69. Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet 2005; 44(3): 221-35.
70. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41(Suppl 5): S333-40.